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Background. Existing diagnostic and treatment tools for human African trypanosomiasis (HAT) are limited.
The recent development of nifurtimox-eﬂornithine combination therapy (NECT) has brought new hopes for pa-
tients in the second stage. While NECT has been rolled out in most endemic countries, safety data are scarce and
derive only from clinical trials. The World Health Organization (WHO) coordinates a pharmacovigilance program
to collect additional data on NECT safety and efﬁcacy. We report here the results of 18 months of experience of
NECT use in treatment centers run by Médecins Sans Frontières in the Democratic Republic of the Congo (DRC).
Methods. This cohort study included 684 second-stage HAT patients (including 120 children) treated with
NECT in Doruma and Dingila hospitals, northeastern DRC, between January 2010 and June 2011. All treatment-
emergent adverse events (AEs) were recorded and graded according to the Common Terminology Criteria for
Adverse Events version 3.0. Safety and efﬁcacy data were retrieved from the WHO pharmacovigilance forms and
from Epitryps, a program monitoring database.
Results. Eighty-six percent of the patients experienced at least 1 AE during treatment. On average, children
experienced fewer AEs than adults. Most AEs were mild (37.9%) or moderate (54.7%). Severe AEs included vomiting
(n = 32), dizziness (n = 16), headache (n = 11), and convulsions (n = 11). The in-hospital case fatality rate was low
(0.15%) and relapses were rare (n = 14).
Conclusions. In comparison with previous treatments, NECT was effective, safe, and well tolerated in nontrial
settings in DRC, further supporting the roll-out of NECT as ﬁrst-line treatment in second-stage Trypanosoma brucei
gambiense HAT. Tolerance was particularly good in children.
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Human African trypanosomiasis (HAT), also known
as sleeping sickness, is a vector-borne disease
transmitted to humans by tsetse ﬂies in sub-Saharan
Africa [1]. It thrives among impoverished populations,
mostly in remote rural areas and conﬂict zones. HAT
is caused by 1 of 2 subspecies of a protozoan parasite.
Trypanosoma brucei (T.b.) gambiense occurs in
Western and Central Africa and is responsible for the
majority of HAT cases, while T.b. rhodesiense is found
in Eastern and Southern Africa [2].
The incidence of reported HAT cases has drastically
decreased in recent years, from >26 000 in 2000 to
<7200 in 2010. However, the true number of cases
may be underestimated by a factor of 4 to 5 [3, 4].
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“Hot spots” still occur in areas of conﬂict or instability, and
large areas in endemic countries have not been surveyed for
decades. In July 2007, Médecins Sans Frontières (MSF) began
population screening for HAT in the districts of Haut-Uélé
and Bas-Uélé in northeastern Democratic Republic of the
Congo (DRC), close to the borders with South Sudan and the
Central African Republic [5].This region is subjected to sus-
tained instability and conﬂict due to the presence of the Lord’s
Resistance Army, a revolutionary group from Uganda.
Through early 2009, screening activities revealed an overall
HAT prevalence rate of 3.4%, reaching 10% in some villages.
HAT due to T.b. gambiense occurs in 2 stages [6]. The he-
molymphatic infection (ﬁrst stage) is characterized by fever,
headache, and joint pain. Transition to the meningoencepha-
litic stage (second stage) occurs after the parasite crosses the
blood-brain barrier. Patients present with neuropsychiatric
symptoms, including sensory motor deﬁcit, walking difﬁcul-
ties, and psychotic behavior, leading to coma and death in the
absence of treatment [7]. Treatment options for HAT are few
and stage-speciﬁc. Of the 5 existing drugs, 3 are active in
second-stage T.b. gambiense HAT [8]: melarsoprol, eﬂorni-
thine, and nifurtimox; all present drawbacks.
Since 1949, melarsoprol intravenous injections have been
the mainstay therapy for second-stage HAT [9]. The drug, an
arsenic derivative, is very toxic. It is associated with severe re-
active encephalopathies in 5%–10% of the cases and kills 3%–
5% of patients [10, 11]. Studies have also shown an increase in
treatment failure rates over recent years [12–14].
Eﬂornithine (D, L, α-diﬂuoromethyleﬂornithine, DFMO)
was shown to be active against T.b. gambiense in the 1980s
[15]. Although better tolerated than melarsoprol, eﬂornithine
also produces several side effects, including gastrointestinal
problems, fever, hypertension, and convulsions [16]. The treat-
ment involves 56 intravenous infusions over 14 days, therefore
requiring complex logistics and trained health staff. The po-
tential for resistance when used in monotherapy is an addi-
tional concern. Several studies have compared the safety and
efﬁcacy of melarsoprol and eﬂornithine. Mortality was found
to be signiﬁcantly lower in patients treated with eﬂornithine
compared to those treated with melarsoprol [17–19].
Nifurtimox, which is registered for the treatment of Chagas
disease, has shown some, albeit limited, efﬁcacy against
second-stage HAT [20–22]. In recent years, combination regi-
mens of the above-mentioned drugs have been evaluated in
second-stage T.b. gambiense HAT. Nifurtimox-eﬂornithine
combination therapy (NECT: oral nifurtimox 15 mg/kg/day
for 10 days plus eﬂornithine infusions 400 mg/kg/day for 7
days) proved to be the best combination in terms of both
safety and efﬁcacy [23–25]. The low mortality (0.7%) and high
cure rates (97.7% at 18 months) reported with NECT prompt-
ed the World Health Organization (WHO) to add the
combination to its Essential List of Medicines in 2009 [26].
However, the population exposed to NECT during clinical
trials was limited (n = 191), and the WHO set up a pharmaco-
vigilance system to monitor the safety of NECT after its roll-
out in endemic countries. In parallel, the Drug for Neglected
Diseases initiative launched a pragmatic trial (NECT-FIELD)
to document the use of NECT as ﬁrst-line therapy for second-
stage HAT under ﬁeld conditions [27].
Since December 2009, MSF has implemented NECT as
ﬁrst-line treatment in all of its programs, including the chal-
lenging region of Haut-Uélé and Bas-Uélé in DRC. Here we
present a retrospective analysis of 684 patients treated with
NECT in the Uélé districts and discuss the safety and feasibili-
ty of this treatment in remote, conﬂict-torn areas.
METHODS
Study Setting
This retrospective cohort study was conducted in the Zones
De Santé of Doruma and Dingila, in the Province Orientale,
northeastern DRC. All second-stage HAT patients diagnosed
on site or by mobile teams were hospitalized in wards set up
by MSF in the reference hospitals (equivalent to district hospi-
tals) of Doruma (Haut-Uélé) or Dingila (Bas-Uélé), both run
by the DRC Ministry of Health.
Participants and Procedures
All second-stage HAT patients treated with NECT between 1
January 2010 and 30 June 2011 were included in the analysis.
Patients were mainly Congolese, with a high proportion of dis-
placed people from neighboring areas owing to rampant
insecurity.
Second-stage HAT was deﬁned by the presence of trypano-
somes in the cerebrospinal ﬂuid (CSF) or a CSF leukocyte
count >5 cells/μL in patients with trypanosomes found in
lymph or blood, or in patients with positive high (1:16) card
agglutination Trypanosoma test (CATT) titer. The CATT is an
agglutination method based on the detection of circulating an-
tibodies against T.b. gambiense [28]. Parasites detection in the
lymph or blood relied on microscopic examination of
samples. Cervical lymph nodes, when present, were punctured
and the ﬂuid was directly observed under microscope for the
presence of motile trypanosomes. Prior to microscopy, blood
samples were subjected to capillary tube centrifugation [29] or
mini-anion exchange centrifugation [30] techniques. CSF was
examined immediately after lumbar puncture, leukocytes were
counted, and trypanosomes were searched for after single cen-
trifugation. Positive laboratory results and CSF leukocyte counts
were conﬁrmed by 2 independent laboratory technicians.
Relapse cases were deﬁned as patients with (1) history of
HAT treatment and (2) presence of trypanosomes in lymph,
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blood, or CSF, or CSF leukocyte count >20 cells/μL, increased
compared with previous count or associated with clinical fea-
tures consistent with HAT. All patients who did not meet this
deﬁnition at 6 or 12 months were considered cured.
Second-stage HAT patients were pretreated with albenda-
zole, and those testing positive for malaria also received oral
artesunate and amodiaquine. All patients received 3 meals per
day (2100 kcal/day for adult patients). NECT (nifurtimox per
oral 5 mg/kg every 8 hours for 10 days and eﬂornithine intra-
venous 200 mg/kg every 12 hours for 7 days) was administrat-
ed to all second-stage HAT patients except pregnant women
(treated with pentamidine intramuscular 4 mg/kg/day for 7
days with NECT administered after delivery) and patients
with signs of hepatic insufﬁciency (treated with eﬂornithine
intravenous 400 mg/kg/day for 14 days). Eﬂornithine was
diluted in distilled water and infused over 2 hours. Nifurtimox
intake was directly observed, administered outside meals, and
readministered if vomiting occurred within 30 minutes. Pa-
tients remained hospitalized during the entire treatment
period. All patients were asked to return for follow-up visits 6,
12, 18, and 24 months after discharge. For patients diagnosed
and treated between 1 January 2010 and 31 December 2010,
treatment outcomes at 6 and 12 months could be assessed.
For patients diagnosed and treated between 1 January 2011
and 30 June 2011, only the treatment outcome at 6 months
was collected. NECT relapses were treated with a combination
of melarsoprol (intravenous 1.2 mg/kg/day) and nifurtimox
(per oral 15 mg/kg/day) for 10 days.
Data Collection
Baseline demographic and clinical characteristics, diagnostic
and treatment data, adverse events, and laboratory follow-up
data were entered in the Epitryps (Epicentre, France) database.
In addition, all treatment-emergent adverse events (AEs) were
recorded in pharmacovigilance forms designed by WHO. AEs
were graded based on the Common Terminology Criteria for
Adverse Events version 3.0. The causality between AE and
NECT was assessed by the treating physician as either not
related, unlikely to be related, possibly related, probably
related, deﬁnitely related, or unknown. The start date and
total duration of each AE were recorded together with the
action taken and the outcome of the AE. Relapses were docu-
mented in WHO relapse forms.
Statistical Analysis
Results are presented with medians and interquartile ranges
(IQRs) for numerical variables, which were compared with the
Student t test. Mann-Whitney U test or Kruskal-Wallis test
was used for nonnormally distributed values. Categorical vari-
ables were compared with χ2 test or Fisher exact test as appro-
priate. Logistic regression was used for univariate and
multivariate analysis of risk factors. Only variables that
showed a signiﬁcant association (P < .05) in the univariate
analysis were included in the multivariate model.
Ethics
The data were collected as part of a routine pharmacovigilance
program. As for most a posteriori studies, individual informed
consent was not deemed necessary in accordance with MSF
Ethics Committee rules [31].
RESULTS
Between 1 January 2010 and 30 June 2011, 1481 HAT patients
were diagnosed and treated by MSF in Doruma and Dingila
(Figure 1). Among 690 second-stage patients, 684 received
NECT, 5 pregnant women were treated with pentamidine, and
1 patient with clinical signs of hepatic insufﬁciency received
eﬂornithine monotherapy. The NECT group composed the
study cohort. Patients treated with NECT had a median age of
36 years (IQR, 20–50 years) and 324 (47.4%) were females. The
cohort included 120 children: 21 (3.1%) <5 years of age and 99
(14.5%) aged 5–15 years. Patients diagnosed by active screening
represented 37.1% (n = 254) of the cohort. Among all patients
treated with NECT, 23 were relapse cases. Table 1 shows the
demographic and clinical characteristics of the cohort.
Adverse Events
Among 684 patients treated with NECT, most (n = 590 [86%])
experienced at least 1 AE during treatment. AEs occurred in
82 of 120 children (67.5%).
A total of 1878 events occurred during hospital stay, with a
mean of 3.2 AEs per patient (range, 1–7). On average, adults
experienced more AEs than children (mean difference = 1.19
AEs per patient; 95% conﬁdence interval [CI], .904–1.475;
P < .001). Most AEs were considered mild (grade 1) (n = 711
[37.9%]) or moderate (grade 2) (n = 1027 [54.7%]) by the
physicians. Severe (grade 3) and very severe (grade 4) AEs
were less frequent (n = 130 [6.9%] and n = 8 [0.4%], respec-
tively). These included vomiting (n = 32), dizziness (n = 16),
headache (n = 11), and convulsions (n = 11). AEs were consid-
ered related (certainly, probably, or possibly) to NECT in
94.3% (n = 1771) of cases by the physicians. All severe and
very severe AEs were considered related to NECT. The in-hos-
pital case fatality rate was low: 0.15% (n = 1). The patient who
died during hospitalization presented with features of reactive
encephalopathy, and the physician in charge considered it to
be related to NECT.
Gastrointestinal AEs were the most frequently reported AEs
(Table 2). Most AEs occurred early during treatment course.
Among children treated with NECT, vomiting (49.2%), ab-
dominal/stomach pain (28.3%), and anorexia (18.3%) were the
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most frequent AEs. Among young (0–4 years) children
(n = 21), vomiting was frequently reported (62%), but none
presented with insomnia or anorexia, and no AE was graded
as very severe.
When compared with the 94 patients who did not experi-
ence AEs, age >15 years increased the probability of having 1
or more AEs by 3.7-fold (Table 3). Presenting with fever on
admission doubled the chances of AE occurrence, while being
diagnosed by active screening decreased the chances by 1.7-
fold. None of the other baseline characteristics included in the
multivariate analysis affected the risk of developing AEs
during treatment.
Adherence to Treatment and Follow-up
Six hundred seventy-seven of 684 patients completed their
treatment. Reasons for discontinuation included death during
treatment (n = 1), treatment toxicity (n = 4), or patient default
(n = 2). Six months of follow-up data were available for 336 of
684 patients (49.1%), and 12 months of follow-up data were
available for 106 of 305 patients (34.8%). At 6 months, 9 pa-
tients (2.7%) were considered to have relapsed (5 had trypano-
somes in the CSF), 4 had died, and 323 (96.1%) were
considered cured. At 12 months, 5 patients (4.8%) were con-
sidered to have relapsed (2 had trypanosomes in the CSF),
and 101 (95.2%) were considered cured. The overall cure rate
was 94.6% (333/352 patients for whom a ﬁnal outcome was
available).
DISCUSSION
NECT showed a relatively good safety proﬁle and good efﬁca-
cy among 684 patients with second-stage T.b. gambiense
HAT treated in 2 hospitals supported by MSF in northeastern
Figure 1. Flowchart of human African trypanosomiasis patients included in the study. Abbreviations: HAT, human African trypanosomiasis; NECT,
nifurtimox-eﬂornithine combination therapy; ttt, treatment.
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DRC, a region characterized by poor health infrastructures, re-
moteness, and insecurity. The in-hospital mortality rate was
very low (0.15%), conﬁrming previous ﬁndings [23–25]. This
ﬁgure corresponds to the lowest case fatality rate ever observed
in HAT programs conducted by MSF, a nongovernmental or-
ganization that has treated approximately 50 000 T.b. gam-
biense HAT patients since 1986. Although the majority of
patients (86%) developed at least 1 AE during treatment, most
events were mild or moderate. Major events (grade 3 and
grade 4) were relatively uncommon (7.4%). These ﬁgures are
lower than those reported by Priotto et al [25] and Checchi
et al [23], who observed major events in 14% and 25%, respec-
tively, of NECT-treated patients. In addition, in contrast with
previous publications, the frequency of seizures among pa-
tients with major AEs remained low (15% [11 of 70 events])
in our study. Vomiting, on the other hand, was the most
common major AE (45.7% [32 of 70 events]). These differenc-
es could be explained by the interobserver variability in
grading AEs.
Strikingly, NECT was better tolerated in children than in
adults. Adults had 4 times more chances to develop 1 or more
AEs, and on average, experienced more events than children.
This may be related to the better safety proﬁle of nifurtimox
in children [33–35], or to a better general condition of chil-
dren on admission, as reﬂected by the better mean Karnofsky
score. Most AEs occurred early during treatment, which sug-
gests that NECT-related AEs do not depend on cumulative
doses. Digestive symptoms were the most common events in
both adults and children. Abdominal pain (40.6%), vomiting
(38.7%), and headache (29.9%) were most frequently observed,
similar to what was reported by others [23–25]. Conversely,
fever was less frequent in our cohort (1.5%; 10 of 684 patients)
as were infections (2.2%; 15 of 684 patients) and diarrhea
(7.2%; 49 of 684 patients). This is likely to be due to the high
proportion (73%) of patients with early second-stage disease
(6–20 cells/μL in the CSF) in our cohort, as this category of
patients was not included in the largest previous report [25].
The pattern of treatment-emergent AEs noted in the present
study is overall consistent with that of nifurtimox and eﬂorni-
thine monotherapies, although the incidence and severity of
speciﬁc AEs appears lower, most likely due to the shorter
treatment duration [16, 36].
The overall cure rate was high (95.1%), and comparable to
the ﬁgures reported earlier [23–25]. Only 14 relapses were re-
ported, of which 9 were diagnosed at the 6-month follow-up
visit, and 5 at the 12-month follow-up visit. We observed a
higher relapse rate when NECT was given for HAT relapse
(7.1%) than in ﬁrst-time treated patients (1.8%). The previous
treatments administered in the 23 relapse patients were pent-
amidine (n = 18), eﬂornithine (n = 5), and unknown (n = 1).
The low number of relapses treated with NECT in our cohort
prevents any deﬁnite conclusion, but this issue should be
studied in larger cohorts.
With only 14 infusions over a week, NECT is much easier
to administer than eﬂornithine monotherapy, entails a de-
creased workload for medical staff, shortens the duration of
hospitalization, and signiﬁcantly reduces costs. Yun et al esti-
mated that the cost of treatment, excluding drug costs, is
reduced from €107 to €39 per patient [37]. Theoretically,
NECT may also prevent the emergence of resistance. The rela-
tive ease of administration allowed a rapid roll-out of NECT
in endemic countries. In 2008, half of stage 2 HAT patients
were still receiving melarsoprol as ﬁrst-line treatment; in 2010
this ﬁgure was reduced to 10% [38]. This shift in treatment
use is most welcome, and should be further encouraged by the
ﬁnding that NECT is well tolerated in the ﬁeld setting.
Table 1. Demographic and Clinical Characteristics of 684
Patients Treated With Nifurtimox-Eﬂornithine Combination Therapy
in Doruma and Dingila, Democratic Republic of the Congo
Patient Characteristics All Patients (N = 684)
Age, y, median (IQR) 36 (20–50)
Age >15 y 564 (82.5)
Female 324 (47.4)
Diagnosed by active screening 254 (37.1)
BMI, kg/m2, median (range)a 19.6 (17.5–21.7)
Body temperature on admission, °C,
median (range)
36.2 (35–38.5)
Malaria coinfection 185 (27)








Behavioral changes 113 (16.5)
Insomnia 35 (5.1)
Convulsion 5 (0.7)
Presence of trypanosomes in CSF 137 (20)
Leukocytes in CSF
6–20 cells/µL 502 (73.4)
21–99 cells/µL 164 (24)
≥100 cells/µL 18 (2.6)
Data are presented as No. (%) unless otherwise specified.
Abbreviations: BMI, body mass index; CSF, cerebrospinal fluid; IQR,
interquartile range.
a BMI was calculated only for patients >5 years of age.
b The Karnofsky performance status score is a quantification of a patient’s
general well-being and activities of daily living [32].
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Table 2. Description of Adverse Events During Nifurtimox-Eﬂornithine Combination Therapy in 684 Patients With Second-Stage Human African Trypanosomiasis in Doruma and
Dingila Hospitals, Democratic Republic of the Congo
Adverse Event No. of Events No. (%) of Patients
No. (%) of
Children (<15 y)




Median d (IQR)1 2 3 4
Stomach/abdominal pain 309 278 (40.6%) 34 (28.3%) 110 (35.6%) 196 (63.4%) 3 (1%) 2 (1–5) 2 (1–3)
Vomiting 265 265 (38.7%) 59 (49.2%) 100 (37.7%) 133 (50.2%) 30 (11.3%) 2 (0.8%) 2 (1–4) 2 (1–3)
Headache 205 205 (29.9%) 14 (11.6%) 97 (47.3%) 97 (47.3%) 11 (5.4%) 2 (1–4) 2 (1–4)
Musculoskeletal pain 204 168 (24.6%) 11 (9.1%) 71 (34.8%) 126 (61.8%) 7 (3.4%) 1.5 (0–4) 1 (1–3)
Anorexiab 144 144 (21.1%) 22 (18.3%) 72 (50%) 67 (46.5%) 4 (2.8%) 5 (3–6) 2 (1–5)
Dizziness 136 136 (19.9%) 3 (2.5%) 50 (36.7%) 70 (51.4%) 16 (11.7%) 5 (2.25–7) 2 (1–4)
Insomnia 82 82 (11.9%) 1 (0.1%) 39 (47.6%) 40 (48.8%) 3 (3.7%) 5 (3–7) 2 (1–3)
Fatigue 76 76 (11.1%) 4 (3.3%) 17 (22.4%) 51 (67.1%) 8 (10.5%) 5 (3–8) 2 (1–3)
Mood/behavior change 61 56 (8.2%) 2 (1.7%) 18 (29.5%) 33 (54.1%) 9 (14.8%) 1 (1.6%) 6 (4–7) 2 (1–1.75)
Nausea 52 52 (7.6%) 1 (0.1%) 29 (55.8%) 21 (40.4%) 2 (3.9%) 2 (1–4) 2 (1–3)
Diarrhea 50 49 (7.2%) 6 (5%) 13 (26%) 30 (60%) 7 (14%) 5 (2–7) 2 (1–3)
Tremor 46 46 (6.7%) 0 (0%) 19 (41.3%) 25 (54.3%) 2 (4.3%) 6 (4–8) 2 (1–3)
Pruritus 30 30 (4.4%) 2 (1.7%) 11 (36.7%) 16 (53.3%) 3 (1%) 4.5 (2.75–6.25) 2 (2–4)
Convulsion 28 28 (4.1%) 2 (1.7%) 6 (21.4%) 11 (39.3%) 10 (35.7%) 1 (3.6%) 5 (2.25–6) 1 (1–2)
Psychosis 20 20 (2.9%) 0 (0%) 3 (15%) 11 (55%) 4 (20%) 2 (10%) 6 (4–7) 2.5 (1–6.25)
Abbreviations: AE, adverse event; IQR, interquartile range..
a Severity was graded from 1 (mild) to 5 (fatal) according to the Common Terminology Criteria for Adverse Events version 3.0.














However, NECT cannot yet be considered as an ideal treat-
ment. The requirement for 7 days of intravenous administration
still represents a deﬁnite obstacle for use in the primary
healthcare setting. Despite the overall good tolerance, some
AEs are troublesome. Vomiting is frequent and may cause in-
sufﬁcient bioavailability of nifurtimox, requiring frequent use
Table 3. Risk Factors for Developing 1 or More Adverse Events Among 684 Second-Stage Human African Trypanosomiasis Patients
Treated With Nifurtimox-Eﬂornithine Combination Therapy in Doruma and Dingila Hospitals, Democratic Republic of the Congo
Patient Characteristic on Admission Univariate OR (95% CI) P Value Multivariate OR (95% CI) P Value
Age >15 y
No 1
Yes 3.965 (2.467–6.372) <.001 3.681 (2.146–6.315) <.001
Sex
Male 1
Female 1.459 (.936–2.275) .095 …
Detected by active screening
No 1
Yes 0.420 (.271–.653) <.001 0.579 (.358–.937) .026
Malaria coinfection
No 1




Yes 1.102 (.652–1.862) .716 …
Arthralgia
No 1
Yes 1.741 (1.115–2.719) .015 0.895 (.533–1.505) .677
Fever
No 1
Yes 2.610 (1.44–4.729) .002 2.191 (1.164–4.123) .015
Headache
No 1
Yes 1.562 (.997–2.448) .052 …
Insomnia
No 1
Yes 2.645 (.624–11.218) .187 …
Pruritus
No 1
Yes 1.884 (1.158–3.067) .011 1.462 (.858–2.492) .163
Psychiatric symptoms
No 1
Yes 1.767 (.886–3.523) .106 …
Somnolence
No 1
Yes 1.392 (.842–2.301) .197 …
Trypanosomes in CSF
No 1
Yes 2.506 (1.224–5.130) .012 1.939 (.922–4.078) .081
Leukocytes in CSF
≤20 × 109 cells/L 1
21–99 × 109 cells/L 2.335 (.808–6.749) .117 …
≥100 × 109 cells/L 3.120 (.996–9.771) .051 …
Abbreviations: CI, confidence interval; CSF, cerebrospinal fluid; OR, odds ratio.
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of antiemetics and occasional readministration of nifurtimox.
Psychotic behavior and convulsions are less frequent but are a
source of distress for patients and relatives, and can be a
source of rumors within local populations. In addition,
NECT is unlikely to be effective against second-stage T.b.
rhodesiense HAT, with melarsoprol left as the only drug
option. To overcome NECT shortcomings, the development
of an oral drug such as fexinidazole holds great promise
[39]. In the meantime, NECT provides a safe and effective
treatment option.
This study bears some limitations. First, heterogeneity in
the reporting of AEs occurred. The number and nature of
the AEs captured in the pharmacovigilance forms varied
between the 3 reporting clinicians during the study period.
In addition, as laboratory investigations were limited, diag-
nosis relied mainly on clinical assessment, impeding conclu-
sive diagnosis of AEs and cause of death. In particular,
hematological abnormalities such as neutropenia, which is a
common side effect of eﬂornithine, could not be assessed.
Also, causality assessment of AEs is highly observer-
dependent, and the absence of a comparative control group
in our study makes it difﬁcult to ascertain the relationship
between the AEs observed and NECT. Hospitalized patients
with second-stage HAT usually have numerous AEs, regard-
less of the regimen used. In most cases, it cannot be conclu-
sively established if the AEs are due to the treatment, to the
disease itself, or to concurrent illnesses. The high proportion
of patients with early second-stage disease may also limit the
external validity of our ﬁndings. Finally, the efﬁcacy of
NECT is likely to be overestimated as 6 and 12 months of
follow-up data were available only for a fraction of patients,
and none were followed up until 24 months. A substantial
proportion of relapses can indeed occur after 12 months fol-
lowing treatment [25].
Nevertheless, this study provides crucial information and
complements the existing safety data generated by the only
randomized controlled trial conducted so far [25]. Of note,
our cohort included 120 children <15 years of age, in whom
NECT was particularly well tolerated, as well as 23 relapse
cases. The population assessed during clinical trials is subject-
ed to speciﬁc inclusion and exclusion criteria, and patients
with comorbidities, pregnant women, children, and the elderly
are systematically excluded. It is therefore particularly impor-
tant to continue assessing the safety of new treatments after
their large-scale introduction in the general population. Phar-
macovigilance programs such as that deployed by WHO are
particularly important. As MSF is one of the main treatment
providers for several neglected tropical diseases, its participa-
tion in pharmacovigilance activities provides crucial comple-
mentary safety data on newly developed therapies such as
NECT. Such involvement makes particular sense, as MSF
initiated and participated in the development of NECT and
other new therapies.
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